Childhood Cancer Insurance Denied: How to Appeal Pediatric Oncology Claim Denials

Childhood cancer is among the most devastating diagnoses a family can face. The good news is that survival rates have improved dramatically over the past five decades, largely because of research conducted through the Children's Oncology Group (COG) and the development of pediatric-specific treatment protocols. The challenging news is that the treatments that save children's lives — clinical trials, specialized drugs, proton therapy — are also among the treatments most frequently denied by insurers.

Clinical Trial Access: Children's Oncology Group

The Children's Oncology Group is the world's largest organization devoted exclusively to childhood and adolescent cancer research, with member institutions across the United States, Canada, and internationally. Most major advances in pediatric cancer treatment have emerged from COG clinical trials.

For many children with cancer, enrollment in a COG trial is not experimental — it is the recommended standard of care according to pediatric oncology specialists. The Affordable Care Act (ACA) requires that health plans cover the routine costs of care associated with participation in a qualifying clinical trial. This includes:

• Routine medical services (hospitalizations, labs, imaging) associated with the trial
• Any other services that would be covered if the patient were not in a trial

The ACA does not require coverage of the investigational drug or device itself (typically provided by the trial sponsor), but it prohibits insurers from dropping a patient from coverage because they enrolled in a trial or from denying routine care costs on the basis of trial participation.

If your insurer has denied coverage for routine care costs associated with a COG trial, this denial likely violates ACA Section 2709 (42 U.S.C. § 300gg-8). Appeal immediately and cite this provision.

Rare Pediatric Cancer Drugs

Childhood cancers are biologically distinct from adult cancers, and many pediatric cancers occur at such low frequencies that standard drug development pathways do not produce treatments specifically approved for children. The FDA has several programs designed to address this gap:

• Orphan Drug Designation: Drugs targeting diseases affecting fewer than 200,000 Americans can receive orphan drug designation. Many pediatric cancer drugs qualify. Orphan designation does not guarantee insurance coverage, but it is evidence that the FDA recognizes the drug as targeting a rare and serious condition.
• Pediatric Priority Review Vouchers: The FDA awards vouchers to developers of drugs for rare pediatric diseases, creating a financial incentive for pediatric drug development.
• Breakthrough Therapy Designation: Drugs showing early evidence of substantial improvement over available therapy can receive this designation, expediting FDA review.

When an insurer denies a pediatric cancer drug as "experimental" or "investigational," the denial may conflict with the drug's FDA designation or approval status. Pull the FDA's drug label and any relevant FDA approval decision documents and include them in your appeal.

Travel to a Children's Oncology Group Center

Not every hospital is equipped to treat childhood cancer. COG centers have the specialized staff, equipment, protocols, and clinical trial access required for optimal pediatric oncology care. Families sometimes must travel significant distances to reach a COG institution.

For commercial insurance, travel coverage for medically necessary care varies by plan. Review your plan documents carefully for any transplant travel benefit, case management travel benefit, or network access exception.

For Medicaid enrollees, non-emergency medical transportation (NEMT) is a federally required benefit under 42 C.F.R. § 431.53. If your child's Medicaid program denied transportation to a COG center, appeal and cite the federal NEMT requirement. State Medicaid programs must ensure access to medically necessary services, which includes transportation.

Proton Therapy for Pediatric Brain Tumors

Proton therapy is a form of radiation therapy that delivers a highly precise dose of radiation to tumors while minimizing damage to surrounding tissue. For pediatric brain tumors, proton therapy is particularly important because children's developing brains are more sensitive to radiation damage than adults'. Reducing radiation exposure to healthy brain tissue can preserve cognitive function, hearing, hormonal development, and long-term quality of life.

Proton therapy is frequently denied by insurers as "experimental" or as having no proven superiority over conventional radiation. This characterization is contested by the pediatric radiation oncology community. For pediatric brain tumors, the dosimetric advantages of proton therapy — sparing critical structures like the cochlea, pituitary gland, and temporal lobes — are well-documented.

To appeal a proton therapy denial for a pediatric brain tumor:

1. Obtain a dosimetric comparison from the treating radiation oncologist showing the dose difference between proton therapy and conventional radiation for the specific tumor location
2. Document the specific critical structures at risk (e.g., cochlea for medulloblastoma, optic pathways for optic glioma)
3. Cite evidence-based literature supporting proton therapy for the specific tumor type and location
4. Reference the National Comprehensive Cancer Network (NCCN) guidelines for the specific pediatric cancer
5. Invoke EPSDT if the child is on Medicaid or CHIP

Fight Back With ClaimBack

When a child has cancer, insurance denials are not abstractions — they are obstacles between a child and life-saving treatment. ClaimBack helps families build urgent, detailed appeals for pediatric oncology denials with the clinical and legal arguments that matter.

Start your childhood cancer appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: Which Should You File?
• Common Reasons Insurance Claims Are Denied